Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...
Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory ...
Fintel on MSN1d
Bernstein Initiates Coverage of Gilead Sciences (GILD) with Outperform RecommendationFintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...
Gilead Sciences GILD has outperformed the market over the past 20 years by 3.74% on an annualized basis producing an average ...
Zacks.com on MSN2d
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowGilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...
We recently made a list of Goldman Sachs’ List Of Stocks Popular With Mutual Fund Managers: Top 20 Stocks. In this piece, we ...
Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.
Houston-based The Normal Anomaly Initiative, a nonprofit with offices in Dallas too that is dedicated to uplifting and ...
On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $84.95 which represents a slight increase of $0.28 or 0.33% from the prior close of $84.67. The stock opened at $84 ...
Like its English-language predecessor, which launched in 2016, this Spanish-language patient community from MyHealthTeam is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback